Several years ago, Gazouli et al. assessed the CRC-targeting ability of bevacizumab-conjugated QDs in vivo, finding that the developed nanosystem was effectively useful to detect VEGF-expressing tumors using fluorescence imaging. Here, VEGFA is linked to colorectal carcinoma.